Cargando…

Ezh2 Acts as a Tumor Suppressor in Kras-driven Lung Adenocarcinoma

Previous studies have suggested that enhancer zeste homolog 2 (Ezh2), a histone methyltransferase subunit of polycomb repressive complex 2 (PRC2), acts as an oncogene in lung adenocarcinoma (ADC) development. However, we found that in human lung ADC samples, deletion and mutations of EZH2 were also...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yanxiao, Hou, Ning, Cheng, Xuan, Zhang, Jishuai, Tan, Xiaohong, Zhang, Chong, Tang, Yuling, Teng, Yan, Yang, Xiao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5441181/ https://www.ncbi.nlm.nih.gov/pubmed/28539837 http://dx.doi.org/10.7150/ijbs.19108

Ejemplares similares

Loss of p53 Attenuates the Contribution of IL-6 Deletion on Suppressed Tumor Progression and Extended Survival in Kras-Driven Murine Lung Cancer
por: Tan, Xiaohong, et al.
Publicado: (2013)

Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities
por: Serresi, Michela, et al.
Publicado: (2018)

Immunoprevention of KRAS-driven lung adenocarcinoma by a multipeptide vaccine
por: Pan, Jing, et al.
Publicado: (2017)

Regulation and Therapeutic Targeting of MTHFD2 and EZH2 in KRAS-Mutated Human Pulmonary Adenocarcinoma
por: Li, Yuchan, et al.
Publicado: (2022)

PRMT5 acts as a tumor suppressor by inhibiting Wnt/β-catenin signaling in murine gastric tumorigenesis
por: Tang, Yuling, et al.
Publicado: (2022)

UHRF1 is a mediator of KRAS driven oncogenesis in lung adenocarcinoma
por: Kostyrko, Kaja, et al.
Publicado: (2023)

KRAS-Driven Lung Adenocarcinoma and B Cell Infiltration: Novel Insights for Immunotherapy
por: Rosamaria, Pinto, et al.
Publicado: (2019)

BRD7 Acts as a Tumor Suppressor Gene in Lung Adenocarcinoma
por: Gao, Yushun, et al.
Publicado: (2016)

Fibroblast Growth Factor—14 Acts as Tumor Suppressor in Lung Adenocarcinomas
por: Turkowski, Kati, et al.
Publicado: (2020)

MiR-138 Acts as a Tumor Suppressor by Targeting EZH2 and Enhances Cisplatin-Induced Apoptosis in Osteosarcoma Cells
por: Zhu, Ziqiang, et al.
Publicado: (2016)

KRAS-driven lung adenocarcinoma: combined DDR1/Notch inhibition as an effective therapy
por: Ambrogio, Chiara, et al.
Publicado: (2016)

Identification of a Clinically Relevant Signature for Early Progression in KRAS-Driven Lung Adenocarcinoma
por: Neidler, Sarah, et al.
Publicado: (2019)

RANKL acts an unfavorable prognostic biomarker and potential target in advanced KRAS‐mutated lung adenocarcinoma
por: Li, Hong‐Shuai, et al.
Publicado: (2023)

Retraction: BRD7 Acts as a Tumor Suppressor Gene in Lung Adenocarcinoma
Publicado: (2023)

KRAS-driven miR-29b expression is required for tumor suppressor gene silencing
por: Thakur, Shilpa, et al.
Publicado: (2017)

p53 inhibitor iASPP is an unexpected suppressor of KRAS and inflammation-driven pancreatic cancer
por: Miller, Paul, et al.
Publicado: (2023)

CBX2 and EZH2 cooperatively promote the growth and metastasis of lung adenocarcinoma
por: Hu, Fei-Fei, et al.
Publicado: (2021)

IKKβ Kinase Promotes Stemness, Migration, and Invasion in KRAS-Driven Lung Adenocarcinoma Cells
por: Rodrigues, Felipe Silva, et al.
Publicado: (2020)

FAM111B enhances proliferation of KRAS‐driven lung adenocarcinoma by degrading p16
por: Kawasaki, Keisuke, et al.
Publicado: (2020)

A mouse model for the study of anti-tumor T cell responses in Kras-driven lung adenocarcinoma
por: Fitzgerald, Brittany, et al.
Publicado: (2021)

KRAS and EGFR mutations coexisting in lung adenocarcinoma
por: Sousa, Vitor, et al.
Publicado: (2010)

EGFR and KRAS Mutations in Patients With Adenocarcinoma of the Lung
por: Jang, Tae Won, et al.
Publicado: (2009)

EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma
por: Chalela, Roberto, et al.
Publicado: (2021)

Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas
por: Baldelli, Elisa, et al.
Publicado: (2021)

Nf1 loss promotes Kras‐driven lung adenocarcinoma and results in Psat1‐mediated glutamate dependence
por: Wang, Xiaojing, et al.
Publicado: (2019)

PPDPF Promotes the Development of Mutant KRAS‐Driven Pancreatic Ductal Adenocarcinoma by Regulating the GEF Activity of SOS1
por: Ni, Qian‐Zhi, et al.
Publicado: (2022)

Apatinib in the treatment of advanced lung adenocarcinoma with KRAS mutation
por: Zeng, Da-xiong, et al.
Publicado: (2017)

Critical requirement of SOS1 for tumor development and microenvironment modulation in KRAS(G12D)-driven lung adenocarcinoma
por: Baltanás, Fernando C., et al.
Publicado: (2023)

A tumor suppressor role for EZH2 in diffuse midline glioma pathogenesis
por: Dhar, Swati, et al.
Publicado: (2022)

PTPN2 regulates the activation of KRAS and plays a critical role in proliferation and survival of KRAS-driven cancer cells
por: Huang, Zhangsen, et al.
Publicado: (2021)

Iron out KRAS-driven cancer
por: Lei, Guang, et al.
Publicado: (2022)

circEZH2(E2) (/E3 ) is a dual suppressor of miR363/miR708 to promote EZH2 expression and prostate cancer progression
por: Su, Zhengzheng, et al.
Publicado: (2022)

ZMAT1 acts as a tumor suppressor in pancreatic ductal adenocarcinoma by inducing SIRT3/p53 signaling pathway
por: Ma, Zuyi, et al.
Publicado: (2022)

KRAS-specific antibody binds to KRAS protein inside colorectal adenocarcinoma cells and inhibits its localization to the plasma membrane
por: Lam, Kuen Kuen, et al.
Publicado: (2023)

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
por: Pao, William, et al.
Publicado: (2005)

Frequency and Spectrum of KRAS Mutations in Moroccan Patients with Lung Adenocarcinoma
por: Elghissassi, Ibrahim, et al.
Publicado: (2014)

Metachronous primary lung adenocarcinomas harboring distinct KRAS mutations
por: Hu, Yan, et al.
Publicado: (2020)

Evaluation of KRAS Concomitant Mutations in Advanced Lung Adenocarcinoma Patients
por: Aran, Veronica, et al.
Publicado: (2021)

Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas
por: Salmón, Marina, et al.
Publicado: (2023)

PCAF-primed EZH2 acetylation regulates its stability and promotes lung adenocarcinoma progression
por: Wan, Junhu, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_43kv11s442ki61uqcanusva3u7